Home › Autosomal Dominant Polycystic Kidney › NCT04111692
A Prospective Observational Study of Foam Sclerotherapy .
A Prospective Observational Study of Foam Sclerotherapy for the Treatment of Symptomatic Kidney or Liver Cysts in Patients With Autosomal Dominant Polycystic Kidney and Liver Disease.
Who can join
Ages 18 to 100 · All sexes
Full eligibility criteria
Inclusion Criteria: * Age ≥18 years * Clinical diagnosis of ADPKD or ADPLD * 1-3 large, non-exophytic liver or kidney cyst * Compressive symptoms from dominant cyst Exclusion Criteria: * Age \<18 years * Absence of ADPKD or ADPLD * Largest cyst \<4cm in all 3 dimensions or largest cyst volume \<400cc * \>3 large, non-exophytic liver or kidney cyst(s) ≥4cm in all 3 dimensions (cyst volume ≥400cc) * Unwilling to comply with study follow-up protocol to 12 ± 1months post-FS * Lacking capacity to provide informed consent to FS of liver or kidney cysts * Pregnancy
About the study
An observational prospective study to determine the impact of foam sclerotherapy of large, dominant kidney/liver cysts on quality of life outcomes and kidney/liver cyst volumes at up to 12 months of follow-up in patients with autosomal dominant polycystic kidney disease (ADPKD) and autosomal dominant polycystic liver disease (ADPLD).
Sponsor: Mayo Clinic · Participants: 100 · Started: Nov 6, 2017
Contact the study team
- Cassie Howe, CRC · Phone: 507-266-1230
Official record on ClinicalTrials.gov — NCT04111692
Locations in the U.S.
| Minnesota | Mayo Clinic, Rochester |
Conditions
From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.